Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, Shankara Paneesha et al.|New England Journal of Medicine|2023Cited by 155
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, John F. Seymour, Eugen Tausch et al.|Blood Advances|2024Cited by 13